clinical trial · NCT06636383
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
Glycogen Storage Disease Type IaNo Intervention
brief summary
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
started
Nov 4, 2024
primary completion
Dec 1, 2036
completion
Dec 1, 2036
last updated
Apr 23, 2026
detailed description
The DTX401-CL401 Disease Monitoring Program (DMP) is a prospective, multicenter, long-term observational study to follow up participants with GSDIa for at least 10 years after the administration of DTX401.
official title
GSDIa Disease Monitoring Program
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol